Ken Griffin Bridge Bio Pharma, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$23.91 - $31.3 $1.95 Million - $2.55 Million	-81,500 Reduced 26.04%	231,500 $5.89 Million
Q2 2024 Aug 14, 2024	SELL	$23.0 - $31.04 $915,400 - $1.24 Million	-39,800 Reduced 11.28%	313,000 $7.93 Million
Q1 2024 May 15, 2024	BUY	$27.35 - $40.45 $831,440 - $1.23 Million	30,400 Added 9.43%	352,800 $10.9 Million
Q4 2023 Feb 14, 2024	SELL	$24.02 - $43.89 $86,472 - $158,004	-3,600 Reduced 1.1%	322,400 $13 Million
Q3 2023 Nov 14, 2023	SELL	$16.89 - $35.01 $3.75 Million - $7.78 Million	-222,300 Reduced 40.54%	326,000 $8.6 Million
Q2 2023 Aug 14, 2023	BUY	$13.29 - $18.01 $4.12 Million - $5.59 Million	310,300 Added 130.38%	548,300 $9.43 Million
Q1 2023 May 15, 2023	BUY	$7.17 - $18.55 $1.27 Million - $3.29 Million	177,200 Added 291.45%	238,000 $3.95 Million
Q4 2022 Feb 14, 2023	BUY	$6.74 - $11.52 $207,592 - $354,816	30,800 Added 102.67%	60,800 $463,000
Q3 2022 Nov 14, 2022	SELL	$7.94 - $12.36 $172,298 - $268,212	-21,700 Reduced 41.97%	30,000 $298,000

291

171M

10.4M

2.37M

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $3.47B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.